Dr. Michael Panny, 3. Medizinische Abteilung, Hanusch Krankenhaus Wien, gibt einen Ausblick auf die wichtigsten Präsentationen beim diffus-großzelligen B-Zell-Lymphom, darunter CAR-T-Zelltherapien, eine mögliche Chemo-Deeskalation bei niedrig-Risiko-Patienten und dem Matrix-RICE-Schema bei ZNS-Befall.

Quelle: ASH Annual Meeting 2019

Abstracts, die im Video erwähnt werden:

Patrick D et al., Abstract 66
66 Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001
https://ash.confex.com/ash/2019/webprogram/Paper127145.html

Reiss D et al., Abstract 202
202 Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response
https://ash.confex.com/ash/2019/webprogram/Paper127683.html

Schuster SJ et al., Abstract 6
6 Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
https://ash.confex.com/ash/2019/webprogram/Paper123742.html

Wilson W et al., Abstract 354
354 Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial
https://ash.confex.com/ash/2019/webprogram/Paper124443.html

Ferreri A et al., Abstract 353
353 Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial
https://ash.confex.com/ash/2019/webprogram/Paper129835.html